2018 American Transplant Congress

June 2-6, 2018 in Seattle, WA

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Short- and Long-Term Outcomes of Interventional Radiology Treatment for Vascular Complications Following Living Donor Liver Transplantation: The Efficacy of Stent Placement

S. Mizuno,¹ A. Nakatsuka,² A. Hayasaki,¹ U. Iizawa,¹ H. Kato,¹ Y. Murata,¹ A. Tanemura,¹ N. Kuriyama,¹ Y. Azumi,¹ M. Kishiwada,¹ M. Usui,¹ H. Sakurai,¹ H. Sakuma,² S. Isaji.¹
Short-Term Outcome Prediction Model in Deceased Donor Kidney Transplant Recipients

K. Archer,¹ Y. Zhang,¹ S. Bontha,² E. Akalin,³ L. Gallon,⁴ D. Maluf,² V. Mas.²
Shortened Cold Ischemia Time and Reduced Incidence of Delayed Graft Function for Kidney Transplants through Enhanced Tissue Compatibility Testing

I. Helanterä,¹ T. Saarinen,² J. Peräsaari,² M. Lempinen,¹ J. Lauronen.²
Shortening Length of Post-Operative In-Patient Stay for Living Kidney Donors

M. Loiselle, H. Bruschwein, J. Jacobs, S. Gulin, T. Rose, H. Arora, R. Nash, A. Toledo, T. Kozlowski.
Should Kidneys from Donation after Cardiac Death Expanded Criteria Donors Be Transplanted?

D. Harriman, J. Rogers, A. Farney, G. Orlando, A. Reeves-Daniel, M. Gautreaux, W. Doares, S. Kaczmorski, R. Stratta.
Should More Donation after Cardiac Death Livers Be Used in Pediatric Transplantation?

C. Hwang,¹ S. Levea,² M. MacConmara.¹
Side Effect Profile of Everolimus in Liver Transplant Patients

F. Kumssa, O. Sadiq, M. Alimirah, R. Kaur, A. Patel, S-.M. Jafri.
Significance of Antibody-Mediated Vascular Rejection (AMVR) on Graft Survival: Correlation with Pure Antibody-Mediated Rejection (AMR)

B. Ozdemir,¹ F. Ozdemir,² A. Terzi,² G. Ozdemir,¹ A. Ok Atilgan,¹ E. Ayvazoglu Soy,³ A. Akdur,³ G. Moray,³ M. Haberal.³
Significant Alteration in Transplant Center Performance Assessment with Extended Patient Follow Up Time

J. Schold, D. Goldfarb, S. Flechner, A. Wee, E. Poggio.
Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections

A. Hauser,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² P. Schenker,¹ M. Junge,³ F. Thaiss,¹ B. Nashan.¹

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z